Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
about
Cancer immunoediting from immune surveillance to immune escapeBiomimetic and synthetic interfaces to tune immune responsesFrom tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumorsMyeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.AACR centennial series: the biology of cancer metastasis: historical perspectiveRevisiting the hallmarks of cancer.Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects.Accumulation of CCR4⁺CTLA-4 FOXP3⁺CD25(hi) regulatory T cells in colon adenocarcinomas correlate to reduced activation of conventional T cellsLiver metastases induce reversible hepatic B cell dysfunction mediated by Gr-1+CD11b+ myeloid cells.Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage.The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy.Conversion of tumors into autologous vaccines by intratumoral injection of α-Gal glycolipids that induce anti-Gal/α-Gal epitope interaction.Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells.The immunotherapy of prostate and bladder cancer.Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusionsReview article: immune suppression and colorectal cancer.Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trialPotential therapeutic role of natural killer cells in cancer.Inflammatory cell infiltration of tumors: Jekyll or Hyde.Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-γ- and TNF-α-co-producing T cell-mediated antitumor immunity.Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.Immunotherapy for renal cell cancer in the era of targeted therapy.How do tumors actively escape from host immunosurveillance?Active immunotherapy: current state of the art in vaccine approaches for NHLCombination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells.Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Myeloid Derived Suppressor Cells: Fuel the Fire.A new method to monitor antigen-specific CD8+ T cells, avoiding additional target cells and the restriction to human leukocyte antigen haplotype.Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells.Dietary mustard seeds (Sinapis alba Linn) suppress 1,2-dimethylhydrazine-induced immuno-imbalance and colonic carcinogenesis in rats.Adenovirus-mediated gene transfer of interleukin-23 shows prophylactic but not therapeutic antitumor effects.Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study.Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response.Amifostine prior to lethal irradiation prevents allogeneic bone marrow engraftment in mice.Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination.Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes
P2860
Q24655415-33570F2C-69E5-471E-82D5-8D04337FFB24Q26801229-55652224-D6CA-4CB0-8BE9-71AF45B2A677Q26865532-A68557B1-B7D2-4614-B55C-50D3A5660447Q33606107-CDF2DE36-2943-4DE7-A058-757355DD533CQ33683443-3039E55E-3F27-476E-A59B-644502C79F9EQ33732986-F0BA3DB4-6142-48AA-9543-02994363C0D0Q34010871-4C9BC8CF-5A35-4B2E-919C-3D081DA5B106Q34154623-359A74DE-FAD3-47D3-BE1F-9509BD213BCEQ34341357-A78D81DD-DAA5-4F02-B11A-8FE290E6D8BCQ34579409-7C2496E1-B9FE-4F40-80C9-4EB4C3278377Q35222365-0570323E-DEE0-4DD8-8378-9FC4A93EB7A9Q35579313-C85A5953-AD90-4222-BCDC-831F258B26ECQ36224502-129AD6BB-901C-425E-A08E-53E536AD373BQ36249962-24CA6962-BD94-4BB7-A8FE-0D157934636DQ36499222-991A2C30-397C-409A-A943-DFF2631D2EFAQ36546883-1CA75861-2BA3-4843-8153-BE18386FA5CEQ36609898-8486FD7B-56AF-41EF-9D3D-41A9920689E8Q36613642-19149B99-5316-4EFB-8939-97797CE6C892Q36675436-ADE37516-3103-4C9F-B0D9-DC4DB0E51DA2Q36918692-34D39F8E-7BAA-458C-B70E-EA6450A16BA6Q36981396-A6635675-E39C-4924-8BC2-B7BF9C385AEBQ37017023-D9F4CE17-12F6-4220-AABA-D82727BB9B79Q37183451-2ABEB5D0-1728-46AE-A7A8-1CDA58EAFE33Q37797963-56D38611-68BA-4500-8CA3-EDAF4F7DF733Q38030484-DFFFC825-0596-4ACC-86C6-5446CC00FD3EQ38167887-D7183528-6B4C-498A-940D-466C62780FE6Q38453610-BAC94DC9-D9EC-4275-BEE5-E8C225049395Q38613648-14B80855-4B8E-42E5-90B7-E7CD6EB6C04DQ38897933-2299F368-2A5B-447E-8FE4-6A4D0870D5F4Q39155197-A4D0ECBC-D894-4DAB-9E33-8D7103C60986Q39379302-1273D999-B6FE-4A9B-8D49-531F9B2C8A4FQ39965317-D946FB7B-8085-4FE8-8329-C3BA1B3CCD1BQ44616182-B5721AC9-2429-4409-9FCC-1DFF4E073F36Q45367630-33E7E8C8-5381-482A-9514-0657E5A0091EQ46774793-83EA6A81-C900-4513-83A0-252ADE03396EQ47358830-C483C1E6-ABC8-41C5-98C9-5DD1F461AA0DQ58621131-7077E841-5E7C-4A49-BC00-F0CBB729D84A
P2860
Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Effective immunotherapy agains ...... suppression and immune escape?
@ast
Effective immunotherapy agains ...... suppression and immune escape?
@en
type
label
Effective immunotherapy agains ...... suppression and immune escape?
@ast
Effective immunotherapy agains ...... suppression and immune escape?
@en
prefLabel
Effective immunotherapy agains ...... suppression and immune escape?
@ast
Effective immunotherapy agains ...... suppression and immune escape?
@en
P1476
Effective immunotherapy agains ...... suppression and immune escape?
@en
P2093
Karl-Johan Malmberg
P2888
P304
P356
10.1007/S00262-004-0577-X
P577
2004-07-28T00:00:00Z